8-K: REGENXBIO Reports Progress in Gene Therapy Programs and Third Quarter 2024 Financial Results

REGENXBIO announced its third quarter 2024 financial results and provided updates on its gene therapy programs, including advancements in trials for Duchenne Muscular Dystrophy, wet AMD, diabetic retinopathy and MPS II.

Summary

• REGENXBIO reported a net loss of $59.6 million for the third quarter of 2024, compared to a net loss of $61.9 million for the same period in 2023.
• The company's revenue decreased to $24.2 million in Q3 2024 from $28.9 million in Q3 2023, primarily due to a decrease in Zolgensma royalty revenues.
• Research and development expenses decreased to $54.4 million in Q3 2024 from $58.2 million in Q3 2023.
• General and administrative expenses decreased to $19.4 million in Q3 2024 from $23.1 million in Q3 2023.
• As of September 30, 2024, REGENXBIO had $278.6 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2026.
• The company is advancing its RGX-202 program for Duchenne Muscular Dystrophy, with the last patient dosed in the pivotal dose expansion cohort for ages 4-11 and the first patient dosed in the cohort for ages 1-3.
• REGENXBIO expects to initiate sites in Canada for RGX-202 in H1 2025.
• A BLA submission for RGX-121 for MPS II has been initiated and is expected to be completed in Q1 2025.
• Positive Phase II data supports bilateral administration of ABBV-RGX-314 for wet AMD, with a 97% reduction in anti-VEGF treatment burden at nine months post-administration.
• An End-of-Phase II meeting for ABBV-RGX-314 in diabetic retinopathy has been accelerated to Q4 2024, with a global pivotal program initiation expected in H1 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials and a strong cash position, the decrease in revenue and net loss temper the overall sentiment. The company is making progress but is not yet profitable.

Positives

• The company's cash runway extends into 2026, providing financial stability for ongoing operations and clinical trials.
• Significant progress has been made in the RGX-202 program for Duchenne Muscular Dystrophy, with dosing completed in key cohorts.
• The BLA submission for RGX-121 for MPS II is underway, potentially leading to the first gene therapy approval for this condition.
• ABBV-RGX-314 has shown strong efficacy in reducing treatment burden for wet AMD, with a 97% reduction in anti-VEGF treatment.
• The acceleration of the End-of-Phase II meeting for ABBV-RGX-314 in diabetic retinopathy indicates a faster path to pivotal trials.
• The company is the only gene therapy sponsor recruiting patients under 4 years old with Duchenne in the U.S.

Negatives

• The company experienced a decrease in revenue from $28.9 million in Q3 2023 to $24.2 million in Q3 2024, primarily due to lower Zolgensma royalty revenues.
• The company reported a net loss of $59.6 million for the third quarter of 2024.
• Cash, cash equivalents and marketable securities decreased from $314.1 million as of December 31, 2023 to $278.6 million as of September 30, 2024.

Risks

• The company's future success depends on the successful completion of clinical trials and regulatory approvals for its gene therapy candidates.
• The company's financial performance is subject to fluctuations in royalty revenues and the costs associated with research and development.
• There are risks associated with the development and commercialization of new products, including the ability to obtain and maintain regulatory approval and intellectual property protection.
• The company's cash runway guidance excludes the impact of any material payments that may potentially be received from partners or licensees upon the achievement of development or regulatory milestones, or upon the approval or commercialization of product candidates.

Future Outlook

REGENXBIO expects its current cash balance to fund operations into 2026, based on current operational plans and excluding potential milestone payments from partners or licensees. The company anticipates several key milestones in the coming quarters, including the completion of the BLA submission for RGX-121, the initiation of pivotal trials for ABBV-RGX-314, and the sharing of a full program update for RGX-202.

Management Comments

• Curran M. Simpson, President and Chief Executive Officer of REGENXBIO, stated that it has been a turning point year for REGENXBIO.
• He highlighted the rapid progress in RGX-202 and its potential to be a best-in-class gene therapy for Duchenne.
• He also noted the near-term filing of the BLA for RGX-121 as a major milestone for the MPS II patient community.
• He emphasized the potential of ABBV-RGX-314 to preserve vision long-term for patients with wet AMD as a one-time treatment for both eyes.

Industry Context

This announcement reflects the ongoing advancements in gene therapy, particularly in the treatment of rare and retinal diseases. REGENXBIO's progress in Duchenne Muscular Dystrophy, wet AMD, diabetic retinopathy, and MPS II positions them as a key player in the field. The collaboration with AbbVie for ABBV-RGX-314 highlights the trend of partnerships between biotech companies to accelerate drug development and commercialization.

Comparison to Industry Standards

• REGENXBIO's 97% reduction in anti-VEGF treatment burden for wet AMD with ABBV-RGX-314 is a significant improvement compared to standard anti-VEGF injections, which require frequent administration.
• The company's focus on one-time gene therapy treatments aligns with the industry's push for more durable and convenient therapies.
• The initiation of a rolling BLA submission for RGX-121 for MPS II is a notable step, as there are limited treatment options for this rare disease.
• The company's cash runway into 2026 is a positive sign, as many biotech companies face funding challenges.
• Compared to companies like Sarepta Therapeutics and BioMarin Pharmaceutical, who also focus on gene therapies for rare diseases, REGENXBIO is demonstrating strong progress in its pipeline.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and net loss, but encouraged by the progress in clinical trials and the company's cash runway.
• Patients with Duchenne Muscular Dystrophy, wet AMD, diabetic retinopathy, and MPS II may benefit from the company's gene therapy programs.
• Employees may be impacted by the company's financial performance and the progress of its clinical trials.
• Partners and licensees may be impacted by the company's progress and the potential for milestone payments.

Next Steps

• REGENXBIO plans to share a full program update for RGX-202 this month, including pivotal trial design and plans for accelerated approval.
• The company expects to complete the BLA submission for RGX-121 in Q1 2025.
• REGENXBIO will initiate sites in Canada for RGX-202 in H1 2025.
• The company expects to initiate the first global pivotal trial for ABBV-RGX-314 in diabetic retinopathy in H1 2025.
• Global regulatory submissions for ABBV-RGX-314 for wet AMD are expected in H1 2026.

Key Dates

Keywords

gene therapy, Duchenne Muscular Dystrophy, wet AMD, diabetic retinopathy, MPS II, RGX-202, ABBV-RGX-314, RGX-121, clinical trials, BLA submission, financial results, biotechnology